CDX
RAJI
Tumor indication
Lymphoma
Tumor subtype
Burkitt's lymphoma
Description
RAJI (Burkitt’s Lymphoma CDX Model)
The RAJI line was derived from a patient with Burkitt’s lymphoma. It is Epstein–Barr virus (EBV)-positive, reflecting a clinically relevant subset of this cancer. RAJI has been a standard B-cell lymphoma model in hematology research. Its reproducibility makes it valuable for translational pipelines.
Key Features:
- Derived from Burkitt’s lymphoma.
- EBV-positive B-cell line.
- Strong growth in xenograft systems.
- Suitable for lymphoma drug research.
Applications:
RAJI is used in studies of B-cell lymphoma biology and EBV-associated oncogenesis. Researchers apply it in testing cytotoxic and targeted therapies. It supports biomarker and immunotherapy research in Burkitt’s lymphoma. Its stability ensures consistency in hematology pipelines.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- Burkitt's lymphoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.